ISTO Technology Announces Phase II Clinical Trials for NuQu Therapy

ISTO Technologies has started a phase-two trial of its NuQu cell-based therapy to further evaluate the efficacy and safety for treatment of pain and disability associated with degenerated spinal discs.

Advertisement

Preliminary results from the phase-one trial indicate promise for patient safety and positive patient outcomes.

The company expects to commence enrollment in the randomized, double-blinded, placebo-controlled trial in the fourth quarter of 2012. Interim results are expected by the end of 2013.

More Articles on Orthopedic Devices:

Globus Medical to Showcase New Spine Surgery Products
Paradigm Spine, OM HealthCare Sign Multiyear Logistics Agreement

Integra LifeSciences Launches Complete Cervical Interbody Fusion Device

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.